Broadening Treatment for Patients with Newly Diagnosed NSCLC
December 8, 2023
December 8, 2024
Jointly provided by by Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the American Lung Association (ALA).
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Date of Release/Expiration
This activity was released on December 4, 2023 and is valid until December 4, 2024. Requests for credit must be made no later than December 4, 2024.
- Physicians - maximum of 1.0AMA PRA Category 1 Credit™
The primary target audience for this activity are medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants.
Overall care for patients with advanced NSCLC can be optimized when clinicians are up to date with the latest immunotherapies, understand how PD-L1 levels affect response to immunotherapy, and are able to select the optimal treatment for each patient. Coordination among multidisciplinary team members and communication with patients for clinical decision-making are critical for improving patient outcomes.
Join thoracic oncologists Dr. Julie Brahmer and Dr. Hossein Borghaei to review practice-changing data on the efficacy and safety of new and emerging treatment strategies with checkpoint inhibitors. The panel will also discuss recent therapy approvals, selection of patients based on PD-L1 and mutational status, minimizing immune-related adverse events, and improving patient quality of life.
After completing this activity, the participant should be better able to:
- Evaluate efficacy data from practice-changing clinical trials on immune checkpoint inhibitors for first-line treatment of NSCLC
- Outline adverse events associated with immunotherapies and approaches to mitigate these effects
- Discuss the effect of PD-L1 expression on outcomes in patients with NSCLC treated with immune checkpoint inhibitors
- Outline strategies to individualize treatment plans for patients with NSCLC through multidisciplinary care and shared decision-making
Julie Renee Brahmer, MD
Co-director of the Upper Aerodigestive Department Bloomberg~Kimmel Institute for Cancer Immunotherapy
The Marilyn Meyerhoff Professor of Thoracic Oncology
Johns Hopkins Kimmel Cancer Center
Hossein Borghaei, DO, MS
Chief of Thoracic Medical Oncology
Professor, Department of Oncology/Hematology
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies
Fox Chase Cancer Center
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Instruction for Participaton and Credit:
Estimated Time to Complete
This activity should take approximately 60 minutes to complete.
Instruction to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 75% on the post-test.
Course Viewing Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For additional information about the accreditation of this activity, please visit https://partnersed.com.
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at [email protected].
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”